Skip to main content
Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience

Fig. 1

Percentage of study participants who met major and minor criteria for inclusion in the NHF omalizumab (OMA) treatment program. The OMA doses, determined according to the manufacture’s recommendations and the drug characteristics, are shown. (ICS, inhaled corticosteroid; BDP, beclomethasone; SCS, systemic corticosteroids; ACQ, asthma control questionnaire; FEV1, forced expiratory volume in one second)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us